New bladder cancer drug shows promise in Late-Stage trial
Disease control
Ongoing
This study tests a new drug, UGN-103, placed directly into the bladder to treat a common type of bladder cancer that hasn't spread deep into the bladder wall. About 99 people with low-grade, intermediate-risk bladder cancer will receive the treatment. The main goal is to see if t…
Phase: PHASE3 • Sponsor: UroGen Pharma Ltd. • Aim: Disease control
Last updated May 14, 2026 12:03 UTC